Mavacamten No Match for Nonobstructive HCM in Phase III Trial

By News Health
3 weeks Ago

(MedPage Today) — MADRID — Mavacamten (Camzyos) failed to replicate its previous successes in hypertrophic cardiomyopathy (HCM) when applied to a population with symptomatic, nonobstructive disease, the phase III ODYSSEY-HCM trial showed….

Source link : https://www.medpagetoday.com/meetingcoverage/esc/117243

Author :

Publish date : 2025-08-30 15:20:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Molecular Imaging Boosted Cancer Detection in Women With Dense Breasts

Europe: B-Cell Therapy Moves Into IgG4-Related Disease

Daylight Saving and Obesity; Serious CGM App Recall; AACE's Strategic Plan

CDC's HIV Prevention Division Readies for Its Demise

We're Focused on School Shootings. But What About Youth Firearm Suicide?

Dr. Trump? President Reprises COVID-Era Role, Now With Unproven Advice on Autism